A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis† ‡
Kittichai Promrat(National Institute of Diabetes and Digestive and Kidney Diseases), Jay H. Hoofnagle(National Institutes of Health), David E. Kleiner(National Institutes of Health), Reneé J. Freedman(Health and Human Development (2HD) Research Network), Glen Lutchman(National Institute of Diabetes and Digestive and Kidney Diseases), Jake T. Liang(National Institutes of Health), Yoon Park(National Institute of Diabetes and Digestive and Kidney Diseases), Gabriel I. Uwaifo(Southern Illinois University School of Medicine), Alejandro Soza(National Institute of Diabetes and Digestive and Kidney Diseases), Jack A. Yanovski(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Theo Heller(National Institutes of Health), Ahalya Premkumar(National Institutes of Health), Edward Doo(National Institutes of Health), Marc G. Ghany(National Institute of Diabetes and Digestive and Kidney Diseases)
Cited by 724
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
|Hepatology|2008|3k
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k